STANDEX INTERNATIONAL CORP annual report, FY2023

Standex International Corporation — FY2023 Form 10-K

Reporting period: Fiscal year ended June 30, 2023, compared primarily with FY2022. The request metadata says “2022 Q4,” but the supplied filing is an annual report for FY2023; it does not provide standalone Q4 results.

Business context and financial highlights

Standex is a diversified industrial manufacturer with five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. Its products serve industrial, transportation, healthcare, aerospace, defense, food-service, and other markets.

MetricFY2023FY2022
Net sales$741.0 million$735.3 million
Gross profit / margin$285.1 million / 38.5%$269.9 million / 36.7%
Operating income$171.1 million$88.3 million
Income from continuing operations$139.2 million$61.5 million
Net income$139.0 million$61.4 million
Diluted EPS$11.58$5.06
Cash from continuing operating activities$90.8 million$78.1 million
Capital expenditures$24.3 million$23.9 million
Cash and cash equivalents at year-end$195.7 million$104.8 million
Long-term debt, net of issuance costs$173.4 million$174.8 million
Net cash (debt)$22.3 million net cash$70.0 million net debt

Gross margin improved 1.8 percentage points. Operating income and EPS include a $62.1 million pretax gain from the Procon divestiture. Excluding that gain, operating income was approximately $109.0 million, up about 23% from FY2022; this is a simple calculation from reported figures, not a company-presented adjusted measure. FY2023 effective tax rate was 15.1%, versus 24.4% in FY2022.

Material changes and segment performance

  • Organic sales rose $39.6 million, or 5.7%, with pricing and demand contributing; currency translation reduced sales by $23.9 million, and divestitures reduced them by $11.9 million. Reported sales increased 0.8%.
  • Electronics sales were $305.9 million, up 0.5%; operating income was $69.0 million, down 2.1%. Currency and inflation weighed on results.
  • Engraving sales were $152.1 million, up 4.0%; operating income rose 16.7% to $25.5 million, with margin increasing to 16.7%.
  • Scientific sales declined 10.6% to $74.9 million as COVID-19 vaccine cold-storage demand eased; operating income fell 4.2% to $17.1 million.
  • Engineering Technologies sales increased 3.8% to $81.1 million; operating income rose 25.9% to $11.1 million.
  • Specialty Solutions sales rose 3.5% to $127.1 million, while operating income increased 62.8% to $25.4 million. Comparability benefited from the absence of a prior-year work stoppage; Procon was divested during FY2023.
  • Backlog realizable within one year declined 7.1% to $238.1 million. Total backlog was $274.9 million, compared with $301.5 million.

Liquidity, capital allocation, and outlook

Operating cash flow increased to $90.8 million. Investing activities provided $41.6 million, including $67.0 million of net closing cash proceeds from the Procon sale, partly offset by $24.3 million of capital spending. Financing activities used $40.0 million, including $25.5 million of share repurchases and $13.0 million of dividends.

The company renewed its revolving credit facility for five years, through February 2028, with a $500 million borrowing limit and a potential $250 million increase subject to conditions. At year-end, borrowings were $175.0 million and reported availability was $371.5 million. The leverage ratio was 0.84:1 against a 3.5:1 covenant ceiling; interest coverage was 20.61:1 against a 2.75:1 minimum. Interest-rate swaps fixed the rate on $175 million of borrowings; the effective borrowing rate was 2.97%.

Management expected continued improvement in key financial metrics in FY2024, supported by productivity initiatives. It anticipated strength in EV-related transportation, commercial aviation and defense, and modestly higher space-market volume; stable vaccine-storage demand, refuse/dump demand, and food-service-equipment demand; and some near-term project timing softness in Engraving, Engineering Technologies, and Specialty Solutions. Expected FY2024 capital spending was $35–$40 million. The company also expected approximately $5 million of additional restructuring costs.

After year-end, Standex acquired Minntronix on July 31, 2023, for approximately $30 million in cash; results are to be reported in Electronics. Management’s capital-allocation strategy includes investment in facilities and growth, acquisitions, dividends, and repurchases. The quarterly dividend has been paid continuously since 1964.

Risks, contingencies, and unusual items

  • Macroeconomic weakness, inflation, customer delays or cancellations, competitive pricing, and demand cyclicality could affect sales and margins. Raw-material, labor, and freight costs, supply availability, and tariffs are additional exposures.
  • International operations expose the company to currency movements, regulation, political and economic instability, and restrictions on cash repatriation. International sales represented 39% of FY2023 sales, down from 42%.
  • Acquisition integration, restructuring execution, and the ability to realize cost savings and synergies present risks. Goodwill and other intangible impairment is also possible; the FY2023 annual goodwill test found no impairment.
  • The primary U.S. defined-benefit pension plan is frozen and underfunded under ERISA measures. The company disclosed required FY2024 U.S. funded-plan contributions of $9.8 million and estimated FY2024 pension contributions/payments of $10.2 million across its plans.
  • Uncertain tax-position liabilities were $9.5 million; the timing of future payments was not reasonably estimable. Operating lease obligations totaled $33.8 million.
  • Standex recorded a $62.1 million Procon sale gain; the reported $67.0 million proceeds were net of closing cash and excluded escrow amounts. It also recorded $3.8 million of restructuring costs. A prior-year $5.7 million litigation accrual was paid in FY2023, and the company received $1.0 million of insurance recovery related to that matter.
  • The auditor issued unqualified opinions on the financial statements and internal control. Revenue recognized over time on customized contracts ($72.4 million) was identified as a critical audit matter because estimates of costs to complete require significant judgment.

Important facts for investors to verify

  • Reconcile reported FY2023 earnings growth with the one-time Procon gain and the related tax benefits; assess underlying operating performance using the company’s segment disclosures.
  • Confirm the final Procon transaction economics, including gross sale price, closing proceeds, escrow, and any retained obligations.
  • Track backlog conversion and demand by segment, particularly the decline in one-year backlog and the expected timing of Engineering Technologies projects.
  • Review the Minntronix acquisition’s purchase price, integration, and subsequent contribution to Electronics results.
  • Monitor FY2024 capital spending, restructuring costs, pension contributions, credit-facility covenant headroom, and cash held outside the United States.
  • Assess sensitivities in over-time contract estimates, commodity and labor costs, foreign exchange, and pension assumptions.